Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Academic Article uri icon

Overview

MeSH

  • Adult
  • Aged
  • Aged, 80 and over
  • Clarithromycin
  • Dexamethasone
  • Female
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Thalidomide
  • Transplantation, Autologous
  • Treatment Outcome

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Multiple Myeloma

abstract

  • We studied T-BiRD (thalidomide [Thalomid(®)], clarithromycin [Biaxin(®)], lenalidomide [Revlimid(®)] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma. In 28-day cycles, patients received dexamethasone 40 mg/day on days 1, 8, 15, 22, clarithromycin 500 mg twice daily on days 1-28; lenalidomide 25 mg/day on days 1-21; and thalidomide 100 mg/day (50 mg/day on days 1-7 of cycle 1 only) on days 1-28. Twenty-six patients received a median of 6 cycles (range 0-41). Overall response rate (ORR) was 80% for the group and 100% in 11 patients who underwent autologous stem cell transplantation as part of first-line therapy. The 4-year overall survival rate was 74.9%, and the median progression-free survival was 35.6 months. Eight patients discontinued due to regimen toxicity. Grade 3 non hematologic toxicity affected 12 patients (46.2%). T-BiRD is a highly active regimen with potential toxicity limitations. ClinicalTrials.gov identifier: NCT00538733.

publication date

  • December 2014

has subject area

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols
  • Clarithromycin
  • Dexamethasone
  • Female
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma
  • Neoplasm Staging
  • Thalidomide
  • Transplantation, Autologous
  • Treatment Outcome

Research

keywords

  • Clinical Trial, Phase II
  • Journal Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.3109/10428194.2014.896005

PubMed ID

  • 24576165

Additional Document Info

start page

  • 2842

end page

  • 2849

volume

  • 55

number

  • 12